Severe COVID-19 Infection in Post Renal Transplant Recipients: A Single Centre Report

Abstract

Kidney transplant recipients are immunocompromised and have been under the spotlight during the COVD-19 pandemic. In our ICU 27.7% of patients received remdesivir as compared to the previous study in which no remdesivir therapy was administered. We did not report any deterioration in renal function secondary to its administration but improved outcome in patients administered the same. Survival rates of patients are thus higher in our subset (53.6%), which included patients with only severe disease.